EGFR and non-small cell lung carcinoma: In NSCLC, EGFR exon 20 insertions mutations account for 1.5-2.5% of all NSCLC, 6% of EGFR-mutated NSCLC, and HER2-20 insertion mutations account for 1.5% (3–5).